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Ubiquitination  was  first  recognized  for  its  function  in 
tagging proteins for destruction by the proteasome [1-5], 
but is now known to be one of the major types of post-
translational  modifications  necessary  for  proper 
functioning of signaling cascades [6-8]. The attachment 
of  ubiquitin  molecules  to  their  targets  occurs  through 
reactions mediated by proteins of three classes, acting in 
sequence:  a  ubiquitin-activating  enzyme,  E1,  which 
contains  an  active-site  cysteine  to  which  the  carboxy-
terminal glycine of ubiquitin becomes attached through a 
reactive thioester bond; a ubiquitin-conjugating enzyme, 
the  E2,  to  which  the  ubiquitin  is  transferred  by  an 
analogous reaction; and a ubiquitin ligase, the E3, which 
catalyzes the attachment of the ubiquitin to a lysine in 
the target protein [4,5,9-11]. Seven of the 76 amino acids 
of ubiquitin are lysines, which can themselves be targeted 
by  ubiquitination  to  generate  polyubiquitin  chains  of 
different linkage types depending on which lysine residue 
acts as the acceptor site for the incoming ubiquitin [12-
14].  In  an  exception  to  this  pattern,  linear  ubiquitin 
chains can be generated by the formation of a peptide 
bond  between  the  carboxy-terminal  glycine  of  the 
incoming and the amino-terminal methionine residue of 
the preceding ubiquitin molecule [15]. Recent research 
has  established  the  identity  and  composition  of  an  E3 
ubiquitin  ligase  that  generates  linear  ubiquitin  chains, 
and has shown that these chains play an important part 
in  several  innate  and  adaptive  immune  signaling 
pathways, including the one triggered by tumor necrosis 
factor  (TNF)  [16-21].  Here  we  review  what  is  known 
about the process by which linear ubiquitin chains are 
assembled, and how they contribute to TNF receptor 1 
(TNFR1) signaling.
LUBAC and the assembly of linear ubiquitin chains
The  assembly  of  linear  ubiquitin  chains  is  unusual  in 
three  ways.  First,  as  we  have  already  mentioned,  the 
linkage does not involve any of the lysine residues in the 
ubiquitin  molecule,  but  occurs  between  the  amino-
terminal methionine of one ubiquitin and the carboxy-
terminal glycine of the next in the chain. For this reason, 
linear  ubiquitin  chains  are  also  known  as  M1-linked 
chains.  The  second  unusual  feature  of  linear  ubiquitin 
chain assembly is that it is the E3 that determines the 
nature of the linkage in these chains [15] – a decision that 
is normally the prerogative of the E2, at least in reactions 
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Ubiquitination now ranks with phosphorylation as one 
of the best-studied post-translational modifications 
of proteins with broad regulatory roles across all of 
biology. Ubiquitination usually involves the addition 
of ubiquitin chains to target protein molecules, and 
these may be of eight different types, seven of which 
involve the linkage of one of the seven internal lysine 
(K) residues in one ubiquitin molecule to the carboxy-
terminal diglycine of the next. In the eighth, the so-
called linear ubiquitin chains, the linkage is between 
the amino-terminal amino group of methionine on a 
ubiquitin that is conjugated with a target protein and 
the carboxy-terminal carboxy group of the incoming 
ubiquitin. Physiological roles are well established for 
K48-linked chains, which are essential for signaling 
proteasomal degradation of proteins, and for K63-
linked chains, which play a part in recruitment of 
DNA repair enzymes, cell signaling and endocytosis. 
We focus here on linear ubiquitin chains, how they 
are assembled, and how three different avenues of 
research have indicated physiological roles for linear 
ubiquitination in innate and adaptive immunity and 
suppression of inflammation.
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E3 is now known to be composed of three proteins. The 
first  two  of  these  –  the  heme-oxidized  IRP2  ubiquitin 
ligase-1  (HOIL-1,  also  known  as  HOIL-1L  and  RBCK1) 
and  the  HOIL-1-interacting  protein  (HOIP,  also  known 
as  RNF31)  –  were  identified  as  part  of  this  multi-
component E3 by Kirisako et al. [15], who also coined the 
term  linear  ubiquitin  chain  assembly  complex  (LUBAC) 
for this novel type of E3.
Subsequent  research,  however,  revealed  that  LUBAC 
also  contains  a  third  component,  SHARPIN  (SHANK-
associated  RH  domain  interacting  protein),  whose 
carboxy-terminal  region  has  high  sequence  similarity 
with  the  amino-terminal  part  of  HOIL-1  [19-21].  The 
structural  features  of  the  three  components  of  LUBAC 
and  their  interactions  are  schematically  illustrated  in 
Figure  1.  All  three  contain  ubiquitin-binding  domains 
whereby they may bind to ubiquitin or to one another 
through  ubiquitin-like  (UBL)  domains.  HOIP  is  the 
central architectural component of the tripartite LUBAC, 
binding  to  both  HOIL-1  and  SHARPIN  through  their 
respective UBL domains. The stoichiometry of the three 
components  that  make  up  the  600  kDa  LUBAC  is 
currently unknown and it is also possible that complexes 
consisting of only two of the three factors exist [15]. In 
addition,  it  appears  that  in  different  cell  types  varying 
amounts  of  HOIL-1,  HOIP  and  SHARPIN  are  present 
independently  of  the  other  LUBAC  components.  It  is 
therefore  possible  that  these  proteins  may  also  serve 
functions  that  are  independent  of  LUBAC  activity 
[19-21].
Several  lines  of  evidence  indicate  that  LUBAC 
generates  exclusively  linear  ubiquitin  chains:  (i)  LUBAC 
can  generate  ubiquitin  chains  with  lysine-less  (K0) 
ubiquitin  in  vitro  [15,18,21];  (ii)  LUBAC  is  unable  to 
generate ubiquitin chains from amino-terminally tagged 
ubiquitin [15,19]; and (iii) mass spectrometric analysis of 
polyubiquitin chains generated in vitro by LUBAC reveals 
linear ubiquitin linkages [15].
Where is the ubiquitin ligase activity of LUBAC and 
how is it activated?
There  are  two  classes  of  E3s:  RING  (really  interesting 
new gene) or U-box-type E3s catalyze the E2-mediated 
transfer of ubiquitin to target proteins [23,24], whereas in 
the  case  of  HECT  (homologous  with  E6-associated 
protein C-terminus)-type E3s ubiquitin is first transferred 
to the E3 by the formation of a thioester bond, and then 
from  the  E3  to  the  substrate.  Both  HOIL-1  and  HOIP 
contain  a  RING-in-between-RING  (IBR)-RING  (RBR) 
domain  (Figure  1),  and  hence  form  part  of  the  RBR 
subclass  of  RING-E3s,  so  in  principle  either  HOIL-1  or 
Figure 1. Schematic representation of the LUBAC components, SHARPIN, HOIP and HOIL-1. There is significant sequence homology (45% 
identity) between the carboxyl terminus of SHARPIN and the amino terminus of HOIL-1, each of which contains a UBL and an NZF motif. HOIP is the 
catalytic subunit of the tripartite LUBAC with SHARPIN and HOIL-1 as accessory factors that bind via their respective UBL domains to the NZF2 and 
UBA domains of HOIP, respectively. HOIP, SHARPIN and HOIL-1 also bind to ubiquitin chains through NZF-mediated interactions. The functions of 
the ZnF domain of HOIP and the coiled-coil domain of SHARPIN are currently unknown. The RBR domain of HOIP, but not of HOIL-1, is responsible 
for linear ubiquitin chain generation by LUBAC. Arrows indicate confirmed interactions between the proteins. Abbreviations: ZnF, zinc finger; NZF, 
Npl4 zinc finger; UBL, ubiquitin-like domain; UBA, ubiquitin-associated domain; IBR, in-between RING domain; RBR, RING-IBR-RING domain.
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Page 2 of 6HOIP  could  account  for  the  ubiquitin  ligase  activity  of 
LUBAC.  However,  the  combination  of  recombinant 
SHARPIN  and  HOIL-1  cannot  generate  linear  ubiquitin 
chains in vitro, whereas recombinant HOIP together with 
HOIL-1  or  SHARPIN  (or  of  course  both)  can;  moreover, 
overexpression of these combinations is also capable of 
activating  NF-kB,  one  of  the  key  transcription  factors 
activated by TNF (see below) [19-21].
This is in line with experiments showing that, despite 
the  fact  that  HOIL-1  and  HOIP  both  contain  an  RBR 
domain (Figure 1), it is the RBR of HOIP that mediates 
the  formation  of  the  linear  ubiquitin  linkage  in  these 
different complexes because the intact RBR of HOIP, but 
not  of  HOIL-1,  is  required  for  LUBAC  activity  [15]. 
Indeed,  despite  its  containing  an  apparently  complete 
RBR domain [25,26], no linear ubiquitination activity has 
so far been detected for recombinant wild-type HOIL-1 
in ubiquitination assays in vitro. It is possible, however, 
that  interactions  with  partners  other  than  HOIP  and 
SHARPIN,  or  perhaps  post-translational  modification, 
may induce its activation.
If  HOIP  is  the  active  E3  in  LUBAC,  what  is  the 
contribution  of  HOIL-1  and  SHARPIN?  The  answer  to 
this question and to the question of HOIL-1 E3 activity 
may  lie  in  a  mechanism  recently  reported  for  Parkin, 
another  RBR-containing  E3,  which  closely  resembles 
HOIL-1  in  domain  structure  [27,28].  Parkin  is  auto-
inhibited  by  its  UBL  and  this  auto-inhibition  may  be 
relieved by binding to a co-factor or a substrate [29]. The 
zinc  finger  and  the  UBL  domains  of  HOIL-1  and 
SHARPIN  are  crucial  for  activation  of  the  linear-
ubiquitin-generating activity of HOIP [16], and it may be 
that  the  binding  of  SHARPIN  and/or  HOIL-1  to  HOIP 
relieves  an  auto-inhibition  in  HOIP  in  a  way  that  is 
analogous  to  the  activation  of  Parkin  by  binding  to  a 
partner  (K  Rittinger  and  B  Stieglitz,  personal 
communication). No qualitative differences have yet been 
discovered  in  the  potential  of  SHARPIN  and  HOIL-1  to 
unleash the linear-ubiquitin-generating capacity of HOIP, 
although  they  seem  likely  to  exist.  It  is  tempting  to 
speculate  that  SHARPIN  and  HOIL-1  may  direct  the 
linear ubiquitination activity of HOIP to different targets.
It remains to be determined whether there are binding 
partners  for  HOIL-1  other  than  HOIP  and  SHARPIN, 
and,  if  so,  whether  this  results  in  HOIL-1-mediated 
generation  of  linear  or  other  ubiquitin  chain  linkages. 
Recent  results  from  Rachel  Klevit  and  colleagues  on 
Parkin  and  another  RBR-domain-containing  protein, 
human homologue of Ariadne (HHARI), may hint at the 
mechanism whereby LUBAC promotes the formation of 
ubiquitin chains. They showed that HHARI, and possibly 
also Parkin, functions as an HECT-like E3 ligase, through 
a conserved cysteine residue in the second RING domain, 
RING2,  that  accepts  a  charged  ubiquitin  in  a  thioester 
intermediate before transferring the bound ubiquitin to a 
substrate  [30].  This  insight  into  mechanism,  however, 
cannot explain the specific generation of linear ubiquitin 
linkages by HOIP, because Parkin is known to generate 
K48- and K63-linked chains [31,32].
Clearly  we  are  only  just  beginning  to  explore  the 
biochemistry  of  linear  ubiquitin  chain  formation  by 
LUBAC, and much remains to be discovered about the 
specificity of this complex in the exclusive generation of 
linear  ubiquitin  chains,  and  the  exact  actions  of  the 
different components within the protein complex.
Linear ubiquitination in the TNF receptor pathway
Ubiquitination  by  K63-  and  K48-linked  chains  was 
already known, before the discovery of linear ubiquitin 
chains, to play an important part in the activation of NF-
kB, arguably the most crucial output of TNFR1 signaling. 
Activation of the TNFR1 pathway occurs when trimeric 
TNF  crosslinks  three  TNFR1  monomers  to  initiate 
formation  of  the  TNFR1  signaling  complex  (TNF-RSC). 
As schematically illustrated in Figure 2, TNFR1 activation 
results in the induction of gene activation by NF-kB and 
mitogen-activated  protein  kinases  (MAPKs)  and, 
depending  on  the  strength  of  these  gene-activatory 
signals, also in cell death, which can be either apoptotic 
(non-inflammatory) or necroptotic (inflammatory).
NF-kB  is  a  central  transcriptional  regulator  in  the 
induction of immune response genes that, in the absence 
of  activating  signals,  is  located  in  the  cytoplasm. 
Activation  of  NF-kB  occurs  through  the  action  of  a 
kinase  complex,  referred  to  as  the  IkB  kinase  (IKK) 
complex, which consists of two catalytic subunits, IKKa 
(IKK1) and IKKb (IKK2), and a critical regulatory subunit 
called  NEMO  (IKKg).  This  complex  is  required  to 
phosphorylate  the  inhibitor  of  NF-kB  (IkB),  thereby 
inducing its degradation and releasing NF-kB to relocate 
to  the  nucleus  and  bind  to  the  promoters  of  immune 
genes.  The  IKK  complex  is  recruited  to  the  TNF-RSC 
through  NEMO,  and  this  results  in  activation  of  the 
kinase activity of this complex. MAPKs are activated as a 
result  of  recruitment  of  the TAB/TAK  complex  into  the 
TNF-RSC.  Whilst  the  TAB/TAK  complex  is  currently 
thought to be recruited exlusively to K63-linked chains 
within  the TNF-RSC,  the  IKK  complex  can  be  recruited 
to this complex via linear chains and, albeit with lesser 
affinity, also via K63- and K11-linked chains [33].
LUBAC  activity  was  first  implicated  in  signaling  from 
TNFR1  when  TNF-mediated  NF-kB  activation  was 
shown  to  be  impaired  in  primary  hepatocytes  from 
HOIL-1 knockout mice, and LUBAC was shown to form 
part of the signaling complex that forms on binding of 
TNF by the receptor, and moreover to be crucial both to 
the  stability  of  the  TNF-RSC  and  in  determining  the 
outcome  of  TNF  signaling  [16-18].  How  LUBAC 
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Page 3 of 6recruitment  to  the  TNF-RSC  influences  signaling 
outcome  is  not  known  in  detail,  but  it  is  known  that 
NEMO, which is the regulatory component of the kinase 
complex that activates NF-kB, recognizes linear ubiquitin 
chains through its specialized ubiquitin-binding domain, 
UBAN  (ubiquitin-binding  domain  present  in  ABINs  and 
NEMO)  [17,34].  The  UBAN  motif  is  known  also  to 
recognize  ubiquitin  chains  with  other  linkages  –  in 
particular  K63  chains,  which  are  also  present  on 
components  of  the  TNF-RSC,  including  on  RIP1  [19]; 
but the UBAN of NEMO binds linear di-ubiquitin with a 
different topology and about 100-fold higher affinity than 
it  does  K63-linked  di-ubiquitin.  This  suggests  that  the 
promotion  of  NF-kB  activation  by  LUBAC  following 
TNF stimulation may be due to linear ubiquitination of a 
component of the signaling complex whereby NEMO is 
recruited to, or retained in, the complex more effectively.
LUBAC  also  linearly  ubiquitinates  NEMO  itself  in  the 
native  TNF-RSC  [19].  TNF-induced  linear  ubiquitination 
of NEMO preferentially occurs on K285 and K309, and in 
cells  expressing  a  NEMO  K285R/K309R  mutant,  NF-kB 
activation  induced  by  LUBAC  overexpression  or  by 
Figure 2. Model of TNFR1 signaling with and without LUBAC activity. Binding of trimeric TNF crosslinks the extracellular domains of three 
TNFR1 molecules and induces the formation of the TNF-RSC (also referred to as complex I). The tripartite LUBAC (ochre) is recruited to the TNF-
RSC in a TRADD-, TRAF2- and cIAP-dependent manner (left panel) [16,19]. LUBAC activity in the TNF-RSC results in linear ubiquitination of RIP1 
and NEMO [19] and enables the NF-kB and MAPK pathways to be activated to their full physiological extent. After a delay, and probably as a 
consequence of deubiquitination events at the membrane-bound TNF-RSC, the composition of the complex changes, and a second complex, 
complex II, appears in the cytosol [45]. Complex II (not shown) recruits FADD and caspase- 8, which are responsible for the induction of apoptosis, 
and includes RIP1 and RIP3, which mediate necroptosis. In the presence of LUBAC, however, the induction of cell death is prevented, probably by 
both stabilization of complex I by linear ubiquitination and the actions of genes induced by the NF-kB and MAPK pathways [16]. In the absence of 
SHARPIN (right panel), the other two LUBAC components are also drastically diminished, TNF-induced gene activation is attenuated and the TNF-
RSC is destabilised, resulting in enhanced complex II formation and, consequently, cell death induction by apoptosis and necroptosis. Note that we 
have drawn the ubiquitin chains as diubiquitins. The actual length of the individual ubiquitin chains attached to components of the TNF-RSC – or 
indeed to components of any other signaling complex – is currently unknown.
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Page 4 of 6stimulation with IL-1b was reduced [18]. The mechanism 
of  linear-ubiquitination-induced  NF-kB  activation  has 
not been solved, but current data indicate that binding of 
NEMO  to  linearly  linked  ubiquitin  induces  a 
conformational change in the helical structure of NEMO 
that may promote the kinase activity of the IKK complex 
[17,35].  Alternatively,  recognition  of  linear  chains  by 
NEMO conjugated to the NEMO molecules of other IKK 
complexes  could  bring  the  kinase  domains  of  the 
respective  IKK  complexes  into  close  proximity,  thereby 
enabling  trans-autophosphorylation  [17],  a  process 
similar to the one that occurs between receptor tyrosine 
kinases when activated by ligand-induced dimerization.
Together, these findings indicate a functional role for 
linear  ubiquitination  in  full  gene  activation  by  the 
signaling  pathways  triggered  by  TNF  in  vivo.  In  the 
absence of LUBAC components the TNF-RSC still forms 
and activation of NF-kB still occurs, albeit at significantly 
reduced levels [20,21]. Experiments with HOIP-deficient 
cells will be needed to strictly corroborate these findings, 
but it is likely that the NF-kB activation that still occurs 
in  the  absence  of  LUBAC  is  mediated  by  K63-  and/or 
K11-linked chains, which are also present in the native 
TNF-RSC  [19]  and  can  also  bind  or  be  attached  to 
NEMO [33,36-39].
Absence  of  LUBAC  components  also  renders  cells 
sensitive  to  TNF-induced  cell  death  [16,20]. 
Intriguigingly, this cell death is not only apoptotic [19,20] 
but also necroptotic [19]. Importantly, this is also true of 
primary  keratinocytes  obtained  from  young,  non-
diseased cpdm mice. These mice, which are genetically 
deficient  in  SHARPIN  and  thus  lack  functional  LUBAC 
complexes  [19],  have  played  a  central  part  in  the 
discovery of the physiological function of LUBAC. They 
present  with  stark  immune  system  developmental 
abnormalities,  and  develop  a  chronic  multi-organ 
inflammatory syndrome with strong manifestation in the 
skin  (hence  the  name  of  this  mutation:  chronic 
proliferative dermatitis (cpdm)) at about 4 to 6 weeks of 
age [40]. The inflammatory syndrome that characterizes 
cpdm  mice  is  apparently  paradoxical,  because  it  is 
generally thought that aberrantly high TNF-induced gene 
activation is the source of inflammation induced by this 
cytokine.  Our  finding  that  TNF  stimulation  results  in 
aberrant death of cpdm-derived cells, and that this cell 
death has both an apoptotic and a necroptotic (and thus 
inflammatory)  component  [19,41,42],  suggested  a 
different explanation: namely, that the inflammation in 
cpdm  mice  could  be  due  to  inflammatory  cell  death 
consequent  on  the  absence  of  SHARPIN-requiring 
LUBAC activity. To investigate this possibility, we crossed 
cpdm  mice  with TNF-deficient  mice,  and  were  able  to 
show that even partial genetic ablation of TNF prevented 
the  formation  of  inflammatory  lesions  in  cpdm  mice, 
indicating  that  TNF-induced  cell  death  is  indeed 
causative  for  the  inflammatory  phenotype  that 
characterizes these mice [19]. It is possible that secondary 
necrosis, which can occur as a consequence of apoptosis, 
may also contribute to inflammation in cpdm mice.
Hence,  linear  ubiquitination  is  implicated  in  two 
different physiological processes: the development of the 
immune  system  and  the  prevention  of  chronic 
inflammation, where the latter effect is achieved through 
interference  with TNF-induced  cell  death. Whether  the 
aberrant cell death in the absence of LUBAC is due to 
reduced gene-inducing capacity of TNF, to a more direct 
effect  of  absence  of  linear  ubiquitin  chains  from  the 
signaling  complexes  induced  by  TNF,  or  perhaps  to  a 
combination  of  both  these  effects  remains  to  be 
established. Our current suggestion for the contribution 
of LUBAC to these pathways is schematically illustrated 
in Figure 2.
What next?
The discovery of linear ubiquitin chains and their specific 
ligase  complex  (LUBAC)  has  sparked  considerable 
interest in the physiological roles of these cellular signals. 
Rapid progress in the delineation of protein assemblies 
involved  in  conjugation  and  recognition  of  linear 
ubiquitination  in  vivo  have  provided  a  platform  for 
addressing new challenges in the field. Among them are 
proteomic studies of the linear ubiquitinome – the set of 
linearly ubiquitinated proteins in cells; analysis at atomic 
resolution  of  protein  complexes  implicated  both  in 
conjugation and recognition functions; and the possibility 
of  finding  novel  regulatory  components  of  LUBAC  by 
identification  of  regulatory  principles  of  LUBAC 
functions and of novel linear ubiquitin binding domains 
(LUBIDs). Interestingly, the new LUBIDs include the zinc 
finger (ZF) domain of HOIL-1, which has recently been 
shown  to  recognize  specifically  linear  ubiquitin  chains 
[43]. One of the greatest challenges, however, will be to 
understand how the different types of ubiquitin linkages 
cooperate to achieve the exact physiologically required 
signaling output, and how this is regulated at the level of 
the  receptor  signaling  complexes.  Identifying  the 
individual  ubiquitination  events  that  occur  in  the TNF-
RSC and determining their respective physiological roles 
is likely to provide valuable insight into biochemistry and 
function of different types of ubiquitinations, including 
linear ubiquitination [44].
Published: 15 March 2012
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